EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Pathogen‐reduced platelet concentrates in France: Impact on the risk of transfusion‐transmitted infections, 2017–2024

Syria Laperche, Virginie de la Taille, Pierre Gallian, Elodie Pouchol, Catherine Humbrecht, Alexandre Montembault, Lucile Malard, Caroline Bacquet, Marianne Asso-Bonnet, Sophie Le Cam iD, Thierry Peyrard iD, Pierre Tiberghien iD

Vox Sanguinis · 2026

DOI: 10.1111/vox.70199 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Vox Sanguinis, 2026. Verfasst von Syria Laperche und 11 weiteren Autor:innen. Beteiligte Einrichtung: Établissement Français du Sang, La Plaine Saint-Denis, France. Hauptthemen laut MEDLINE: Platelet Transfusion, Blood Platelets, Blood Safety, Transfusion Reaction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Pathogen reduction (PR) using amotosalen‐UVA was implemented for 100% of platelet concentrates (PCs) in France in November 2017. No bacterial testing was in place earlier. The impact of PR on the risk of transfusion‐transmitted infections (TTIs) from November 2017 to December 2022 (vs. January 2013 to October 2017) has been published previously. To further assess the impact of PR implementation, the evaluation period was expanded to December 2024. Materials and Methods PC‐associated TTIs occurring in 2023 and 2024 were analysed and included in the assessment.

Results

Two cases of PC‐associated transfusion‐transmitted bacterial infections (TTBIs) were reported. The first involved Bacillus mobilis in a split pooled whole blood–derived PC. This Grade 2 TTBI was diagnosed following identification of the same pathogen in the second PC unit, quarantined for failed swirling test. The second involved Staphylococcus ureilyticus in an apheresis PC transfused to a patient who subsequently died. TTBI frequency decreased from 1/97,098 PC ( n = 15 over 5 years, 2 deaths) to 1/787,662 PC ( n = 3, over 7 years, 1 death) after PR implementation ( p < 0.001). No human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T‐cell lymphotropic virus (HTLV) or arboviruses TTI were reported from 2013 to 2024. No further cases of PC‐associated hepatitis E virus (HEV) TTI were reported, concomitantly to HEV‐nucleic acid testing implementation. A PC‐associated parvovirus B19 TTI occurred in 2024. The use of PR PCs facilitated PC supply during arboviral outbreaks.

Conclusion

The reduction in PC‐related TTBIs following PR implementation is confirmed. However, the recent occurrence of two severe TTBI cases highlights a persistent risk. Prevention of PR‐PC‐associated TTIs by non‐enveloped viruses requires specific screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet TransfusionBlood PlateletsBlood SafetyTransfusion ReactionBlood-Borne InfectionsHumansFranceFurocoumarinsFemaleMale

Stichwörter der Autor:innen

pathogen reductionplatelet transfusiontransfusion‐transmitted bacterial infectiontransfusion‐transmitted infection

Substanzen

amotosalenFurocoumarins

Autor:innen und Institutionen

  • Établissement Français du Sang, La Plaine Saint-Denis, France.
  • Établissement Français du Sang, Strasbourg, France.
  • Etablissement Français du Sang, Créteil, France.
  • UMR RIGHT 1098, Université Marie et Louis Pasteur, INSERM, Etablissement Français du Sang, Besançon, France.

ORCID-Profile: Sophie Le Cam, Thierry Peyrard, Pierre Tiberghien

Zitieren

APA

Laperche, S., de la Taille, V., Gallian, P., Pouchol, E., Humbrecht, C., Montembault, A., Malard, L., Bacquet, C., Asso-Bonnet, M., Le Cam, S., Peyrard, T., & Tiberghien, P. (2026). Pathogen‐reduced platelet concentrates in France: Impact on the risk of transfusion‐transmitted infections, 2017–2024. Vox Sanguinis. https://doi.org/10.1111/vox.70199

Vancouver

Laperche S, de la Taille V, Gallian P, Pouchol E, Humbrecht C, Montembault A, et al. Pathogen‐reduced platelet concentrates in France: Impact on the risk of transfusion‐transmitted infections, 2017–2024. Vox Sanguinis. 2026. doi:10.1111/vox.70199

BibTeX
@article{Laperche2026,
  author = {Laperche, Syria and de la Taille, Virginie and Gallian, Pierre and Pouchol, Elodie and Humbrecht, Catherine and Montembault, Alexandre and Malard, Lucile and Bacquet, Caroline and Asso-Bonnet, Marianne and Le Cam, Sophie and Peyrard, Thierry and Tiberghien, Pierre},
  title = {Pathogen‐reduced platelet concentrates in France: Impact on the risk of transfusion‐transmitted infections, 2017–2024},
  journal = {Vox Sanguinis},
  year = {2026},
  doi = {10.1111/vox.70199}
}
Kostenlos starten →